Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Study Suggests Emergency Contraception Potential For Regular Use

This article was originally published in The Tan Sheet

Executive Summary

Authors of a literature review suggest that 0.75 mg doses of levonorgestrel, currently used as an emergency contraceptive, may be safe and effective as a primary means of birth control in some populations but note that "rigorous new" safety and efficacy data would be needed to support such use.

You may also be interested in...

Teva's Plan B One-Step OTC Application Puts FDA On The Spot

Teva Pharmaceutical Industries asks FDA to allow over-the-counter sales of Plan B One-Step, starting the likely final leg of the emergency contraceptive's journey toward OTC status.

FDA Will Wait To Act On Plan B Petition Despite Contempt Complaint

FDA does not plan to look at allowing wider access to nonprescription emergency contraceptive Plan B until Teva Pharmaceuticals files an application, despite a complaint accusing the agency of ignoring a court order to reconsider age restrictions on the product.

Unilever Announces Corporate Restructuring Amid Reports Of Activist Investor Influence

Around 1,500 senior and junior management roles will be cut under Unilever’s announced plan to reshape its corporate matrix, the firm reports on 25 January. The news comes a day after reports that activist investor Nelson Peltz of Trian Fund Management has taken a stake in the business.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts